{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T09:23:24Z","timestamp":1763198604846,"version":"3.45.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100015661","name":"UCB Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015661","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s13555-025-01545-5","type":"journal-article","created":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T09:10:21Z","timestamp":1758877821000},"page":"3765-3776","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prevalence and Trends in Systemic Treatment for Pediatric Psoriasis in the USA between 2015 and 2021"],"prefix":"10.1007","volume":"15","author":[{"given":"Anna","family":"Ramond","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theresa","family":"Rosario-Jansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinyu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy S.","family":"Paller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,26]]},"reference":[{"key":"1545_CR1","first-page":"187","volume":"17","author":"AS Paller","year":"2018","unstructured":"Paller AS, Singh R, Cloutier M, Gauthier-Loiselle M, Emond B, Gu\u00e9rin A, et\u00a0al. Prevalence of psoriasis in children and adolescents in the United States: a claims-based analysis. J Drugs Dermatol. 2018;17:187\u201394.","journal-title":"J Drugs Dermatol"},{"key":"1545_CR2","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1093\/ced\/llae276","volume":"50","author":"V Shah","year":"2024","unstructured":"Shah V, Larson A, Jafferany M. Exploring the psychological impact of childhood-onset psoriasis: a systematic review. Clin Exp Dermatol. 2024;50:29\u201337.","journal-title":"Clin Exp Dermatol"},{"key":"1545_CR3","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.3892\/etm.2021.10864","volume":"22","author":"DE Branisteanu","year":"2021","unstructured":"Branisteanu DE, Georgescu S, Serban IL, Pinzariu AC, Boda D, Maranduca MA, et\u00a0al. Management of psoriasis in children (review). Exp Ther Med. 2021;22:1429.","journal-title":"Exp Ther Med"},{"key":"1545_CR4","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/jid.2012.339","volume":"133","author":"R Parisi","year":"2013","unstructured":"Parisi R, Symmons DP, Griffiths CE, Ashcroft DM, Identification, Management of P, et\u00a0al. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133:377\u201385.","journal-title":"J Invest Dermatol"},{"key":"1545_CR5","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1093\/ced\/llae282","volume":"49","author":"LMH Arancio","year":"2024","unstructured":"Arancio LMH, D\u2019Amico D, Dastoli S, Fiorella CS, Manfredini M, Moretta G, et\u00a0al. Early intervention and cumulative life course impairment in psoriasis: a review. Clin Exp Dermatol. 2024;49:1525\u201331.","journal-title":"Clin Exp Dermatol"},{"key":"1545_CR6","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jaad.2019.08.049","volume":"82","author":"A Menter","year":"2020","unstructured":"Menter A, Cordoro KM, Davis DMR, Kroshinsky D, Paller AS, Armstrong AW, et\u00a0al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients. J Am Acad Dermatol. 2020;82:161\u2013201.","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"1545_CR7","doi-asserted-by":"publisher","first-page":"3221","DOI":"10.1007\/s13555-023-01051-6","volume":"13","author":"RE Tao","year":"2023","unstructured":"Tao RE, Pixley JN, Holovach PG, Fleischer AB Jr., Feldman SR. Management of pediatric psoriasis: a U.S. survey based on visits from the National Ambulatory Medical Care Survey (NAMCS). Dermatol Ther (Heidelb). 2023;13(12):3221\u20137.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1545_CR8","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1007\/s13555-022-00761-7","volume":"12","author":"M Sticherling","year":"2022","unstructured":"Sticherling M, McPherson T, de Lucas Laguna R, Costanzo A, Reed C, Artime E, et\u00a0al. Patient characteristics and treatment patterns in European pediatric patients with psoriasis: a real-world, cross-sectional study. Dermatol Ther (Heidelb). 2022;12:1793\u2013808.","journal-title":"Dermatol Ther (Heidelb)"},{"unstructured":"US Food and Drug Administration. ENBREL\u00ae (etanercept) prescribing information. Volume 2024.","key":"1545_CR9"},{"key":"1545_CR10","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.jdrv.2024.12.008","volume":"3","author":"A Firek","year":"2025","unstructured":"Firek A, Castelo-Soccio L. Pediatric psoriasis: biologics and oral small molecule inhibitors in modern therapy. JAAD Rev. 2025;3:51\u20136.","journal-title":"JAAD Rev"},{"unstructured":"US Food and Drug Administration. HUMIRA\u00ae (adalimumab) prescribing information. Volume 2024.","key":"1545_CR11"},{"unstructured":"US Food and Drug Administration. REMICADE\u00ae(infliximab) prescribing information. Volume 2024.","key":"1545_CR12"},{"unstructured":"US Food and Drug Administration. STELARA\u00ae (ustekinumab) prescribing information. Volume 2024.","key":"1545_CR13"},{"key":"1545_CR14","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s40272-021-00443-5","volume":"23","author":"M Nogueira","year":"2021","unstructured":"Nogueira M, Paller AS, Torres T. Targeted therapy for pediatric psoriasis. Paediatr Drugs. 2021;23:203\u201312.","journal-title":"Paediatr Drugs"},{"issue":"1","key":"1545_CR15","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.jaad.2019.05.056","volume":"82","author":"P Lansang","year":"2020","unstructured":"Lansang P, Bergman JN, Fiorillo L, Joseph M, Lara-Corrales I, Marcoux D, et\u00a0al. Management of pediatric plaque psoriasis using biologics. J Am Acad Dermatol. 2020;82(1):213\u201321.","journal-title":"J Am Acad Dermatol"},{"unstructured":"US Food and Drug Administration. TALTZ\u00ae (ixekizumab) prescribing information. Volume 2024.","key":"1545_CR16"},{"unstructured":"US Food and Drug Administration. COSENTYX\u00ae (secukinumab) prescribing information. Volume 2024.","key":"1545_CR17"},{"key":"1545_CR18","doi-asserted-by":"publisher","first-page":"360","DOI":"10.3899\/jrheum.171315","volume":"46","author":"K Raimundo","year":"2019","unstructured":"Raimundo K, Solomon JJ, Olson AL, Kong AM, Cole AL, Fischer A, et\u00a0al. Rheumatoid arthritis-interstitial lung disease in the United States: prevalence, incidence, and healthcare costs and mortality. J Rheumatol. 2019;46:360\u20139.","journal-title":"J Rheumatol"},{"unstructured":"US Food and Drug Administration. OTEZLA\u00ae (apremilast) prescribing information. Volume 2025, 2021.","key":"1545_CR19"},{"key":"1545_CR20","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1001\/jamadermatol.2013.1078","volume":"149","author":"AS Paller","year":"2013","unstructured":"Paller AS, Mercy K, Kwasny MJ, Choon SE, Cordoro KM, Girolomoni G, et\u00a0al. Association of pediatric psoriasis severity with excess and central adiposity: an international cross-sectional study. JAMA Dermatol. 2013;149:166\u201376.","journal-title":"JAMA Dermatol"},{"key":"1545_CR21","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1111\/j.1440-0960.2012.00878.x","volume":"53","author":"S Kapila","year":"2012","unstructured":"Kapila S, Hong E, Fischer G. A comparative study of childhood psoriasis and atopic dermatitis and greater understanding of the overlapping condition, psoriasis-dermatitis. Australas J Dermatol. 2012;53:98\u2013105.","journal-title":"Australas J Dermatol"},{"key":"1545_CR22","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1111\/bjd.15021","volume":"176","author":"DA Springate","year":"2017","unstructured":"Springate DA, Parisi R, Kontopantelis E, Reeves D, Griffiths CE, Ashcroft DM. Incidence, prevalence and mortality of patients with psoriasis: a U.K. population-based cohort study. Br J Dermatol. 2017;176:650\u20138.","journal-title":"Br J Dermatol"},{"key":"1545_CR23","doi-asserted-by":"publisher","DOI":"10.1097\/JW9.0000000000000112","volume":"9","author":"A Gonzalez-Cantero","year":"2023","unstructured":"Gonzalez-Cantero A, Constantin MM, Dattola A, Hillary T, Kleyn E, Magnolo N. Gender perspective in psoriasis: a scoping review and proposal of strategies for improved clinical practice by European dermatologists. Int J Womens Dermatol. 2023;9:e112.","journal-title":"Int J Womens Dermatol"},{"key":"1545_CR24","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1111\/bjd.19169","volume":"184","author":"IYK Iskandar","year":"2021","unstructured":"Iskandar IYK, Parisi R, Griffiths CEM, Ashcroft DM. Systematic review examining changes over time and variation in the incidence and prevalence of psoriasis by age and gender. Br J Dermatol. 2021;184:243\u201358.","journal-title":"Br J Dermatol"},{"key":"1545_CR25","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1093\/bjd\/ljac021","volume":"188","author":"D Tha\u00e7i","year":"2023","unstructured":"Tha\u00e7i D, Vender R, de Rie MA, Conrad C, Pariser DM, Strober B, et\u00a0al. Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trial. Br J Dermatol. 2023;188:22\u201331.","journal-title":"Br J Dermatol"},{"key":"1545_CR26","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1001\/jamadermatol.2022.0364","volume":"158","author":"L Pina Vegas","year":"2022","unstructured":"Pina Vegas L, Penso L, Claudepierre P, Sbidian E. Long-term persistence of first-line biologics for patients with psoriasis and psoriatic arthritis in the French health insurance database. JAMA Dermatol. 2022;158:513\u201322.","journal-title":"JAMA Dermatol"},{"key":"1545_CR27","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1002\/pds.5229","volume":"30","author":"H Lee","year":"2021","unstructured":"Lee H, He M, Cho SK, Bessette L, Tong AY, Merola JF, et\u00a0al. Validation of claims-based algorithms to identify patients with psoriasis. Pharmacoepidemiol Drug Saf. 2021;30:868\u201374.","journal-title":"Pharmacoepidemiol Drug Saf"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01545-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01545-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01545-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T09:22:05Z","timestamp":1763198525000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01545-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,26]]},"references-count":27,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1545"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01545-5","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"type":"print","value":"2193-8210"},{"type":"electronic","value":"2190-9172"}],"subject":[],"published":{"date-parts":[[2025,9,26]]},"assertion":[{"value":"18 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Anna Ramond and Theresa Rosario-Jansen: employees and shareholders of UCB. Xinyu Yang: received compensation for activities with Parexel International as an employee. Amy S. Paller: received investigator fees from AbbVie, Dermavant, Eli Lilly and Company, Johnson & Johnson Innovative Medicine, and UCB and received honoraria from AbbVie, Arcutis, Boehringer Ingelheim, Dermavant, LEO Pharma, and UCB.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study was conducted in accordance with the principles of the Declaration of Helsinki. MarketScan data are collected as part of billing for routine patient care and de-identified before access is granted to researchers; therefore, no Institutional Review Board review or patient consent was needed. The data were accessed in compliance with US data privacy regulations, including the Health Insurance Portability and Accountability Act. The dataset does not contain any direct patient identifiers, and the research team had no access to identifiable private information at any point; therefore, no Institutional Review Board review or patient consent was needed.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"All the results presented in this article are in aggregate form, and no personally identifiable information was used for this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}}]}}